Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Spectral Medical ( (TSE:EDT) ) has shared an announcement.
Spectral Medical has delayed the timing of its Premarket Approval submission to the U.S. Food and Drug Administration for its PMX-20R hemoadsorption device to treat endotoxic septic shock, now targeting around late April to mid-May 2026 instead of the original Q1 2026 goal. The company is incorporating complete 12-month mortality data from its Tigris study and finalizing non-clinical elements such as human factors engineering testing to strengthen the application.
Management believes that including full 12-month mortality outcomes will enhance the total body of clinical evidence and facilitate the FDA’s review of PMX for endotoxic septic shock. Spectral expects to report topline 12-month mortality data in late May or early June 2026 and continues to work closely with regulators, aiming to position PMX for an efficient review process and bolster its footing in the high-need septic shock treatment market.
The most recent analyst rating on (TSE:EDT) stock is a Hold with a C$1.50 price target. To see the full list of analyst forecasts on Spectral Medical stock, see the TSE:EDT Stock Forecast page.
Spark’s Take on TSE:EDT Stock
According to Spark, TipRanks’ AI Analyst, TSE:EDT is a Neutral.
The score is weighed down primarily by weak financial performance—large ongoing losses, persistent cash burn, negative equity, and rising debt—implying high funding risk. Technicals are moderately supportive with mild positive momentum, but valuation remains constrained by negative earnings and no dividend data.
To see Spark’s full report on TSE:EDT stock, click here.
More about Spectral Medical
Spectral Medical Inc. is a late-stage theranostic company focused on developing treatments and diagnostic tools for sepsis and septic shock. Its lead product, the Toraymyxin (PMX) hemoperfusion device, removes endotoxin from the bloodstream and is guided by the company’s FDA-cleared Endotoxin Activity Assay, with approvals in Japan, Europe, and Canada and over 360,000 units used worldwide.
Average Trading Volume: 53,268
Technical Sentiment Signal: Strong Buy
Current Market Cap: C$400.8M
See more data about EDT stock on TipRanks’ Stock Analysis page.